Exicure announces $5 million raise in private placement transaction priced at market premium

Chicago--(business wire)--exicure, inc.® (nasdaq:xcur), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting rna to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that it has agreed to sell an aggregate of 26,021,111 shares of its common stock at a purchase price of $0.1937 per share to certain accredited investors in a private placement in public equity (“pipe”) financing. the p
XCUR Ratings Summary
XCUR Quant Ranking